A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors

BACKGROUND: Deregulation of FGF19-FGFR4 signaling is found in several cancers, including hepatocellular carcinoma (HCC), nominating it for therapeutic targeting. FGF401 is a potent, selective FGFR4 inhibitor with antitumor activity in preclinical models. This study was designed to determine the reco...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Stephen L., Schuler, Martin, Kang, Yoon-Koo, Yen, Chia-Jui, Edeline, Julien, Choo, Su Pin, Lin, Chia-Chi, Okusaka, Takuji, Weiss, Karl-Heinz, Macarulla, Teresa, Cattan, Stéphane, Blanc, Jean-Frederic, Lee, Kyung-Hun, Maur, Michela, Pant, Shubham, Kudo, Masatoshi, Assenat, Eric, Zhu, Andrew X., Yau, Thomas, Lim, Ho Yeong, Bruix, Jordi, Geier, Andreas, Guillén-Ponce, Carmen, Fasolo, Angelica, Finn, Richard S., Fan, Jia, Vogel, Arndt, Qin, Shukui, Riester, Markus, Katsanou, Vasiliki, Chaudhari, Monica, Kakizume, Tomoyuki, Gu, Yi, Porta, Diana Graus, Myers, Andrea, Delord, Jean-Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161616/
https://www.ncbi.nlm.nih.gov/pubmed/35655320
http://dx.doi.org/10.1186/s13046-022-02383-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161616/
https://www.ncbi.nlm.nih.gov/pubmed/35655320
http://dx.doi.org/10.1186/s13046-022-02383-5

Ejemplares similares